JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide, today announced the Company’s presentation at the American College of Radiation Oncology (ACRO) 2022 Summit on March 11, 2022, from 12:00-1:00pm EST at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.
JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients. BioCurity announces the expansion of the Company’s Intellectual Property portfolio for its supportive care drugs under development generated from the Company’s cerium oxide nanoparticle technology which includes an intravenous (IV) formulation for the protection of normal internal tissue from radiation damage and a topical formulation for the protection of a cancer patient’s skin from burns, scars, and skin dermatitis. BioCurity offers the potential to prevent the often-devastating side effects associated with radiation therapy and to enhance the treatment outcomes for patients.
JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide, today announced an abstract regarding the Company’s proprietary technology on cerium oxide nanoparticle was accepted for a poster presentation at the American College of Radiation Oncology (ACRO) 2022 Summit, taking place March 9 - 12, 2022 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.